OpenURL Connection Search

Select item for more details and to access through your institution.

Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
Published in:
Journal of Oncology Navigation & Survivorship, 2019, v. 10, n. 11, p. 498
By:
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- Simkovic, Martin;
- Kaplan, Polina;
- Kraychok, Iryna;
- Illes, Arpad;
- De La Serna, Javier;
- Dolan, Sean;
- Campbell, Phillip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, E. J.;
- Jae Hoon Lee;
- Tianling Chen;
- Wei Liang;
- Patel, Priti;
- Jurczak, Wojciech
Publication type:
Article
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S280, doi. 10.1016/j.clml.2019.07.217
By:
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- Simkovic, Martin;
- Kaplan, Polina;
- Kraychok, Iryna;
- Illes, Arpad;
- De La Serna, Javier;
- Dolan, Sean;
- Campbell, Phillip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, Eric J.;
- Lee, Jae Hoon;
- Liang, Wei;
- Patel, Priti;
- Quah, Cheng;
- Jurczak, Wojciech
Publication type:
Article
Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results.
Published in:
Journal of Oncology Navigation & Survivorship, 2020, v. 11, n. 11, p. 437
By:
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- Simkovic, Martin;
- Kaplan, Polina;
- Kraychok, Iryna;
- Illes, Arpad;
- de la Serna, Javier;
- Dolan, Sean;
- Campbell, Philip;
- Musuraca, Gerardo;
- Jacob, Abraham;
- Avery, Eric J.;
- Jae Hoon Lee;
- Wang, Denise;
- Patel, Priti;
- Jurczak, Wojciech
Publication type:
Article

Found: 3

Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.

Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results.